Body composition and phase angle by bioimpedance in patients with MAFLD

OBJECTIVETo describe the characteristics of the body components and phase angle (PhA) of patients with MAFLD according to those different to fibrosis and hepatic steatosis. MATERIAL AND METHODSObservational and descriptive study in a cohort of 585 volunteers from our center with MAFLD criteria. The...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gastroenterología y hepatología 2022-08, Vol.45 (7), p.535-542
Hauptverfasser: Pinto Gálvez, Samanta Mayanin, García-Mora, Uriel, Salgado-Álvarez, Giovanni Alejandro, Cano-Contreras, Ana Delfina, Durán-Rosas, Cristina, Priego-Parra, Bryan, Triana-Romero, Arturo, Amieva-Balmori, Mercedes, Roesch-Dietlen, Federico, Francisco, María Del Rocío, Chi-Cervera, Luis Alberto, Bernal-Reyes, Raúl, Martínez-Vázquez, Sophia, Martinez-Rodriguez, Leonardo Alberto, Méndez-Guerrero, Osvely, Icaza-Chávez, María Eugenia, Remes-Troche, José María
Format: Artikel
Sprache:eng ; spa
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:OBJECTIVETo describe the characteristics of the body components and phase angle (PhA) of patients with MAFLD according to those different to fibrosis and hepatic steatosis. MATERIAL AND METHODSObservational and descriptive study in a cohort of 585 volunteers from our center with MAFLD criteria. The risk of liver fibrosis was determined by APRI, NAFLD score and FIB-4; at an indeterminate and high risk of fibrosis, a transient elastography (Fibroscan®) were realized. Bioimpedance body composition analysis (SECA®) was performed. Patients with ET and SECA® registry were included. Bioimpedance body composition analysis (SECA®) was performed. Patients with ET and SECA® registry were included. RESULTS125 participants (21.4%) were evaluated, age 53.9±13.9 years, 62.1% women, BMI 33.2±5.8kg/m2. The SECA® analysis showed mean fat mass of 42%±7.32 and muscle mass 21.18kg±6.6. The PhA was 5.1±0.69, in women 4.92±0.62 and men 5.41±0.70. PhA in patients without fibrosis was 5.091 vs with fibrosis 5.121 (P=.813). In advanced fibrosis, it reported a low value compared to the rest of the groups (P=.031). The PhA in S3 was higher compared to S1 and S2 (5.3 vs 4.82, 4.81) (P=.027). CONCLUSIONSIn MAFLD, the PhA was lower than the healthy Mexican population. In patients without fibrosis and severe steatosis, PhA rises proportionally to the increase in fat mass and BMI and in advanced liver fibrosis, PhA decreases.
ISSN:0210-5705
DOI:10.1016/j.gastrohep.2021.10.003